EuroSIDA study group: Decline in the AIDS and death rates in the EuroSIDA study: an observational study, Lancet, issue.9377, pp.36222-36251, 2003. ,
Trend over calendar time in virological failure in HIV-infected patients treated for at least six months with combined antiretroviral therapy in France (FHDH ANRS CO04)InPaper presented at: 6 th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, p.104, 2011. ,
Recommandations du groupe d'experts 2013 Prise en charge médicale des personnes vivant avec le VIH ,
T Cells, The Journal of Infectious Diseases, vol.200, issue.8, pp.2001212-1215, 2009. ,
DOI : 10.1086/605890
Markers of Inflammation, Coagulation, and Renal Function Are Elevated in Adults with HIV Infection, The Journal of Infectious Diseases, vol.201, issue.12, pp.2011788-1795, 2010. ,
DOI : 10.1086/652749
HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy, PLoS ONE, vol.12, issue.10, p.7658, 2009. ,
DOI : 10.1371/journal.pone.0007658.s004
Valganciclovir Reduces T Cell Activation in HIV-Infected Individuals With Incomplete CD4+ T Cell Recovery on Antiretroviral Therapy, Journal of Infectious Diseases, vol.203, issue.10, pp.2031474-1483, 2011. ,
DOI : 10.1093/infdis/jir060
Epstein-Barr Virus load and immune activation in Human Immunodeficiency Virus type 1-infected patients, Journal of Clinical Virology, vol.53, issue.3, pp.195-200 ,
DOI : 10.1016/j.jcv.2011.12.013
Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation, Top HIV Med, vol.18, issue.1, pp.2-6, 2010. ,
Regulatory T Cells and HIV-1 Infection, Viral Immunology, vol.21, issue.3, pp.285-291, 2008. ,
DOI : 10.1089/vim.2008.0006
Antiprotéases Cohorte (APROCO) Study Group: Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy, Clin Infect Dis, issue.10, pp.341396-1405, 2002. ,
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review, AIDS, vol.20, issue.17, pp.2165-2174, 2006. ,
DOI : 10.1097/QAD.0b013e32801022eb
French Hospital Database on HIV-ANRS CO4: Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population, AIDS, vol.2010, issue.8, pp.241228-1230 ,
The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study, International Journal of Cancer, vol.45, issue.2, pp.467-475, 2011. ,
DOI : 10.1002/ijc.25903
Premature age-related comorbidities among HIVinfected persons compared with the general population, Clin Infect Dis, issue.11, pp.531120-1126, 2011. ,
French Hospital Database on HIV (FHDH)?ANRS CO4: HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals, Clin Infect Dis, vol.2012, issue.554, pp.600-607 ,
Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus???Infected Patients<subtitle>A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4</subtitle><alt-title>Antiretroviral Drugs, Risk of MI, and HIV</alt-title>, Archives of Internal Medicine, vol.170, issue.14, pp.1228-1238, 2010. ,
DOI : 10.1001/archinternmed.2010.197
Association Between Systemic Inflammation and Incident Diabetes in HIV-Infected Patients After Initiation of Antiretroviral Therapy, Diabetes Care, vol.33, issue.10, pp.2244-2249, 2010. ,
DOI : 10.2337/dc10-0633
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus, JAMA, vol.286, issue.3, pp.327-334, 2001. ,
DOI : 10.1001/jama.286.3.327
C-reactive protein: a new risk assessment tool for cardiovascular disease, J Am Osteopath Assoc, vol.105, issue.9, pp.409-416, 2005. ,
How much is too much? Interleukin-6 and its signalling in atherosclerosis, Thrombosis and Haemostasis, vol.102, issue.2, pp.215-222, 2009. ,
DOI : 10.1160/TH09-05-0297
Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection, PLoS Medicine, vol.180, issue.10, p.203, 2008. ,
DOI : 10.1371/journal.pmed.0050203.sd002
Gut epithelial barrier dysfunction, inflammation and coagulation predict higher mortality during treated HIV/AIDS.InPaper presented at: 19 th Conference on Retroviruses and Opportunistic Infections, Abstract, vol.278, 2012. ,
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case?control study, BMC Infect Dis, vol.2013, issue.131, p.414 ,
AIDS Clinical Trials Group: Soluble markers of inflammation and coagulation, but not T-cell activation predict non-AIDS defining events during suppressive antiretroviral therapy Abstract 790, 20 th Conference on Retroviruses and Opportunistic Infections, 2013. ,
SPIRAL Trial Group: Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir, AIDS, vol.2012, issue.18, pp.262315-2326 ,
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment, AIDS, vol.23, issue.12, pp.1547-1556, 2009. ,
DOI : 10.1097/QAD.0b013e32832cbcc2
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir, AIDS, vol.26, issue.11, pp.261371-1385 ,
DOI : 10.1097/QAD.0b013e328354f4fb
Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients, PLoS ONE, vol.5, issue.10, p.13188, 2010. ,
DOI : 10.1371/journal.pone.0013188.s002
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study, Antiviral Therapy, vol.19, issue.2, 2013. ,
DOI : 10.3851/IMP2681
Systemic Effects of Inflammation on Health during Chronic HIV Infection, Immunity, vol.39, issue.4, pp.633-645 ,
DOI : 10.1016/j.immuni.2013.10.001
Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung Cancer, JNCI Journal of the National Cancer Institute, vol.103, issue.14, pp.1112-1122, 2011. ,
DOI : 10.1093/jnci/djr216
INSIGHT Study Group: Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of http antiretroviral therapy (ART) are associated with increased risk of AIDS or death, J Infect Dis, vol.14122, issue.11, pp.2031637-1646, 2011. ,
Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection, Journal of Infectious Diseases, vol.203, issue.6, pp.780-790, 2011. ,
DOI : 10.1093/infdis/jiq118
Persistent Microbial Translocation and Immune Activation in HIV???1???Infected South Africans Receiving Combination Antiretroviral Therapy, The Journal of Infectious Diseases, vol.202, issue.5, pp.723-733, 2010. ,
DOI : 10.1086/655229
A Plasma Biomarker Signature of Immune Activation in HIV Patients on Antiretroviral Therapy, PLoS ONE, vol.118, issue.2, p.30881 ,
DOI : 10.1371/journal.pone.0030881.s003
Microbial translocation in HIV infection: causes, consequences and treatment opportunities, Nature Reviews Microbiology, vol.10, issue.9, pp.655-666 ,
DOI : 10.1038/nrmicro2848
HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS, Curr HIV Res, vol.2011, issue.93, pp.148-153 ,
Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy, Journal of Antimicrobial Chemotherapy, vol.68, issue.8, pp.681857-1861 ,
DOI : 10.1093/jac/dkt120
Immunologic Failure Despite Suppressive Antiretroviral Therapy Is Related to Activation and Turnover of Memory CD4 Cells, Journal of Infectious Diseases, vol.204, issue.8, pp.2041217-1226, 2011. ,
DOI : 10.1093/infdis/jir507
T Cell Count in HIV???Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy, The Journal of Infectious Diseases, vol.197, issue.1, pp.126-133, 2008. ,
DOI : 10.1086/524143
Lymphocyte Responses to Chemokines, International Reviews of Immunology, vol.4, issue.3-4, pp.3-4323, 1998. ,
DOI : 10.1083/jcb.134.1.255
Analysis of the Immune Responses in Chimpanzees Infected with HIV Type 1 Isolates, AIDS Research and Human Retroviruses, vol.24, issue.4, pp.573-586, 2008. ,
DOI : 10.1089/aid.2007.0182
Acute Plasma Biomarkers of T Cell Activation Set-Point Levels and of Disease Progression in HIV-1 Infection, PLoS ONE, vol.7, issue.10, p.46143 ,
DOI : 10.1371/journal.pone.0046143.s007
Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Na??ve HIV-1???Infected Patients, AIDS Research and Human Retroviruses, vol.26, issue.5, pp.533-540, 2010. ,
DOI : 10.1089/aid.2009.0177
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs, The Lancet, vol.381, issue.9883, pp.3812109-2117 ,
DOI : 10.1016/S0140-6736(13)60104-X